May 21, 2019

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Mothers Code: 4593)

Athersys Presents Data from its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference

HEALIOS K.K. ("Healios") is developing a new treatment for Acute Respiratory Distress Syndrome (ARDS) [*1] in Japan using the stem cell product HLCM051 (MultiStem®) [*2], for which the patent and licensing rights are held by Athersys, Inc ("Athersys").

We are delighted to report that Athersys announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation yesterday at the American Thoracic Society International Conference in Dallas, Texas, the longest running, large-scale conference in the world offering groundbreaking research in pulmonary, critical care and sleep medicine. His talk was titled, "Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)".

An announcement from Athersys can be found at the following link:
https://www.athersys.com/investors/press-releases/press-release-details/2019/Athersys-Presents-Data-From-Its-Acute-Respiratory-Distress-Syndrome-Clinical-Trial-at-American-Thoracic-Society-International-Conference/default.aspx

"We are pleased with the positive results from Athersys' MUST-ARDS trial," commented Hardy TS Kagimoto, MD, CEO of HEALIOS K.K. "To echo Dr. Bellingan's comments, there is no cure for ARDS and we too are excited about the potential for having a therapy for the patients suffering from it. Towards that end, we will steadily carry out our pneumonia-induced ARDS focused ONE-BRIDGE study in cooperation with the investigators in Japan."

*1. Acute Respiratory Distress Syndrome (ARDS)
ARDS is a general term for the symptoms of acute respiratory failure suddenly occurring in seriously ill patients. The major causes are severe pneumonia, septicemia, trauma etc.
Inflammatory cells are activated in response to these diseases or injuries, causing damage to the tissue of the lungs. As a result, water accumulates in the lungs, leading to acute respiratory failure. According the ARDS

treatment guideline 2016, the mortality rate is approximately 30 to 58%.

Artificial respiration using an endotracheal tube or mask is used to treat respiratory failure in an intensive care unit. However, it is known that prolonged use of a ventilator worsens a patient's prognosis. There is demand for a new treatment for ARDS that will lead to improvement in patients' symptoms and prognosis.

*2. HLCM051

HLCM051 is a somatic stem cell regenerative medicine product. Healios added it to its pipeline by signing an exclusive licensing agreement with the United States based Athersys in January 2016, whereby Healios acquired rights to develop and distribute Athersys' proprietary stem cell product MultiStem® to treat ischemic stroke in Japan. Further, in June 2018 Healios and Athersys expanded their collaboration broadly, and as part of this expansion Healios acquired the development and distribution licenses to use MultiStem® to treat ARDS in Japan.

Contact:
Department of Corporate Communications, HEALIOS K.K.
Mail: ir@healios.jp